» Articles » PMID: 30488368

Risk Factors for Carbapenem-resistant Enterobacteriaceae Infections: a French Case-control-control Study

Overview
Publisher Springer
Date 2018 Nov 30
PMID 30488368
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

This study aimed to assess characteristics associated with infections due to carbapenem-resistant Enterobacteriaceae (CRE), producing (CPE) or not producing (non-CPE) carbapenemase, among hospitalised patients in 2014-2016 in France. Case-patients with CRE were compared to two control populations. In multivariate analysis comparing 160 CRE cases to 160 controls C1 (patients with a clinical sample positive for carbapenem-susceptible Enterobacteriaceae), five characteristics were linked to CRE: male gender (OR = 1.9; 95% CI = 1.3-3.4), travel in Asia (OR = 10.0; 95% CI = 1.1-91.2) and hospitalisation in (OR = 2.4; 95% CI = 1.3-4.4) or out of (OR = 4.4; 95% CI = 0.8-24.1) France in the preceding 12 months, infection in the preceding 3 months (OR = 3.0; 95% CI = 1.5-5.9), and antibiotic receipt between admission and inclusion (OR = 1.9; 95% CI = 1.0-3.3). In multivariate analysis comparing 148 CRE cases to 148 controls C2 [patients with culture-negative sample(s)], four characteristics were identified: prior infection (OR = 3.3; 95% CI = 1.6-6.8), urine drainage (OR = 3.0; 95% CI = 1.5-6.1) and mechanical ventilation (OR = 3.7; 95% CI = 1.1-13.0) during the current hospitalisation, and antibiotic receipt between admission and inclusion (OR = 6.6; 95% CI = 2.8-15.5). Univariate analyses comparing separately CPE cases to controls (39 CPE vs C1 and 36 CPE vs C2) and non-CPE cases to controls (121 non-CPE vs C1 and 112 non-CPE vs C2), concomitantly with comparison of CPE to non-CPE cases showed that only CPE cases were at risk of previous travel and hospitalisation abroad. This study shows that, among CRE, risk factors are different for CPE and non-CPE infection, and suggests that question patients about their medical history and lifestyle should help for early identification of patients at risk of CPE among patients with CRE.

Citing Articles

Risk factors for Carbapenem-resistant Enterobacterales infections: A case-control study.

Mbele S, Vasaikar S S Afr Fam Pract (2004). 2025; 67(1):e1-e10.

PMID: 39935157 PMC: 11886460. DOI: 10.4102/safp.v67i1.6029.


Clinical Predispositions, Features, and Outcomes of Infections with Carbapenem-resistant among Critical Care Patients.

Shoala A, Nassar Y, El-Kholy A, Soliman N, Abdel-Fattah A, El-Ghawaby H Indian J Crit Care Med. 2025; 29(1):36-44.

PMID: 39802247 PMC: 11719537. DOI: 10.5005/jp-journals-10071-24876.


Population-Based Study of Emergence and Spread of Escherichia coli Producing OXA-48-Like Carbapenemases, Israel, 2007-2023.

Temkin E, Bechor M, Lurie-Weinberger M, Keren-Paz A, Chen D, Lugassy C Emerg Infect Dis. 2024; 31(1):66-74.

PMID: 39714269 PMC: 11682801. DOI: 10.3201/eid3101.240722.


Predictors of Mortality, Drug Resistance, and Determinants among Carbapenem-Resistant Infections in Chinese Elderly Patients.

Zhang Y, Zou C, Qin J, Li M, Wang X, Wei T Can J Infect Dis Med Microbiol. 2024; 2024:5459549.

PMID: 39234528 PMC: 11374419. DOI: 10.1155/2024/5459549.


[DISTRIBUTION OF CARBAPENEMASES IN TUNISIAN BURN PATIENTS].

Mokline A, Zarrouk S, Jemi I, Fraj H, Gasri B, Ben Saad M Ann Burns Fire Disasters. 2024; 37(2):106-111.

PMID: 38974797 PMC: 11225287.


References
1.
Harris A, Karchmer T, Carmeli Y, Samore M . Methodological principles of case-control studies that analyzed risk factors for antibiotic resistance: a systematic review. Clin Infect Dis. 2001; 32(7):1055-61. DOI: 10.1086/319600. View

2.
Paterson D . Extended-spectrum beta-lactamases: the European experience. Curr Opin Infect Dis. 2002; 14(6):697-701. DOI: 10.1097/00001432-200112000-00006. View

3.
Pitout J, Laupland K . Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis. 2008; 8(3):159-66. DOI: 10.1016/S1473-3099(08)70041-0. View

4.
Schwaber M, Carmeli Y . Carbapenem-resistant Enterobacteriaceae: a potential threat. JAMA. 2008; 300(24):2911-3. DOI: 10.1001/jama.2008.896. View

5.
Kaniga K, Flamm R, Tong S, Lee M, Friedland I, Redman R . Worldwide experience with the use of doripenem against extended-spectrum-beta-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies. Antimicrob Agents Chemother. 2010; 54(5):2119-24. PMC: 2863686. DOI: 10.1128/AAC.01450-09. View